Pharma Marketletter articles from July 2005

Pharma Marketletter archives from July 2005

Working together for self-care: UK's lead in prescription to OTC switching.(Over-the-Counter)
July 4, 2005... The subject of switching prescription medicines to over-the-counter status was a recurring theme at the recent joint meeting of the World Self-Medication Industry and the Association of the European Self-Medication Industry (AESGP) held in...

Norway: five-month pharma imports.(Brief Article)
July 4, 2005... Norway imported pharmaceutical and medicinal products worth 3.47 billion kroner ($531.00) million during the first five months of 2005, a year-on-year increase of 7.4%, according to new data from Statistics Norway.

Hungary widens Rx reference pricing.(National Health Insurance Fund, OEP)(Brief Article)
July 4, 2005... Hungary's National Health Insurance Fund, the OEP, says the July 1 introduction of wider therapeutic reference pricing will produce 4.30 billion forint ($21.32 billion) savings. The move extends fixed reimbursement to 1,885 products (a...

Hungary non-reimbursed market: liberalization slow.(Brief Article)
July 4, 2005... Hungary's newly-passed Pharmaceutical Market Regulations Act consists mainly of changes to bring the country into line with the European Union. They include strengthening the rules on clinical trials and packing instructions, and give...

Euro CV guideline: "90% of over-50s are sick".(cardiovascular)
July 4, 2005... New European guidelines that set ever lower threshholds for normal blood pressure and cholesterol mean that 90% of people aged over 50 could be labeled as sick, according to an article by two physicians published in the June 25 issue of the...

PhRMA slams AARP Rx import study findings.
July 4, 2005... US seniors' advocacy group the AARP has published the results of an investigation which it commissioned to discover the experience of parallel trading in pharmaceuticals in European Union member states and to understand the implications of...

New Yorkers "oppose EBM plan," says poll.(Evidence-based medicine)(Brief Article)
July 4, 2005... Patient advocates in the US state of New York have attacked the evidence-based medicine model developed by Oregon's Center for Evidence-Based Policy, which NY State Governor George Pataki intends to use for his preferred drug list policy...

Indian panel urges more drugs for price control.(Brief Article)
July 4, 2005... In a new report to the Indian government, an official task force recommends extending state price controls to more than 40% of medicines on the market, which have a retail value of over 230.00 billion rupees ($5.28 billion) a year. Currently,...

Bangladesh pharma exports soar since 2001.(Brief Article)
July 4, 2005... Bangladesh exported pharmaceuticals and drug raw materials worth about 15.39 billion taka ($242.07 million) to 62 countries last year, up from 321.8 million taka to just 17 nations in 2001, say new data reported by the Bangladesh Observer....

Independent drug regulator for India.(Brief Article)
July 4, 2005... An independent drugs regulatory authority is to be set up by the Indian government, Union Health and Family Welfare Minister Anbumani Ramadoss has announced at a meeting of the Drugs Consultative Committee. Noting that India has the world's...

Double-digit antivirals growth set to peak.(Brief Article)
July 4, 2005... The excellent recent growth rates of the world market for prescription antiviral drugs will peak at nearly 17% during 2005-6 and fall to more modest levels by the end of the decade, says a new study from Kalorama Information. HIV/AIDS will...

Geron refines hESC culture protocol.(Brief Article)
July 4, 2005... Geron Corp of the USA says that studies published in the on-line journal Biotechnology and Bioengineering show that human embryonic stem cells can be cultured at scale in a chemically-defined, serum-free medium without the use of animal-derived...

No allergic reactions from Halozyme's rHuPH20.(Halozyme Therapeutics)(recombinant human hyaluronidase)(Brief Article)
July 4, 2005... US drugmaker Halozyme Therapeutics has reported results from a clinical trial demonstrating the absence of allergic reactions to its recombinant human hyaluronidase and significantly reduced injection-site discomfort compared to the saline...

Biogen Idec's Rituxan and galiximab gives 12 months EFS.(event-free survival)(Brief Article)
July 4, 2005... US biotechnology firm Biogen Idec says that a Phase II clinical study demonstrated that its Rituxan (rituximab), in combination with another monoclonal anticancer antibody galiximab, may prolong event-free survival in patients with relapsed or...

Adventrx' CoFactor sees good Ph II data.(Brief Article)
July 4, 2005... San Diego, USA-based Adventrx Pharmaceuticals has reported complete response data from all 48 measurable patients in a 50-patient Phase II trial of its candidate anticancer drug candidate CoFactor and 5-fluorouracil as a first-line treatment...

Immune Resp's NeuroVax: promising results.(Brief Article)
July 4, 2005... The USA's Immune Response Corp, an immuno-therapeutics firm focused on HIV and multiple sclerosis, says that results from an ongoing clinical study of its investigational T cell receptor peptide vaccine, NeuroVax, demonstrated that it can...

Gilead to pull out of Tamiflu deal with Roche.(Brief Article)
July 4, 2005... US firm Gilead Sciences says that it has delivered a notice of termination to Swiss drug major Roche "for material breach of the parties' 1996 development and license agreement for Tamiflu (oseltamivir)," and is seeking to terminate the accord...

Growing OTC substance abuse in US eating disorder patients.(Brief Article)
July 4, 2005... In the USA, women and teens with eating disorders are spending billions of dollars on over-the-counter medications to help control their weight. Eating disorder patients tend to abuse laxatives, appetite suppressants, diet and water pills....

India Pharma Fund launched.(India Pharma Fund Limited)(Brief Article)
July 4, 2005... The India Pharma Fund Limited has completed a fundraising of $27,0 million and has been listed on the Channel Islands Stock Exchange. The Net Asset Value for both classes of shares, on inception, was $9.68. As at June 16, the net asset value of...

Peregrine reveals $6.7M share buy by one investor.(Brief Article)
July 4, 2005... California, USA-based Peregrine Pharmaceuticals says that it has signed a definitive agreement for the offer and sale of eight million shares of common stock to one institutional investor in exchange for net proceeds of $6.72 million. The...

Pfizer repatriates foreign earnings, to buy back $5B shares.(Brief Article)
July 4, 2005... Pharmaceutical giant Pfizer says that its board has approved the repatriation, under the American Jobs Creation Act of 2004, of an additional $8.6 billion in foreign earnings beyond the initial $28.3 billion previously announced by the firm...

Australia: one of the largest world's biotech IP pools.(intellectual property)
July 4, 2005... Australia, known globally for its biotechnology R&D capabilities and strengths in human therapeutics, agribiotech, diagnostics, medical devices and biodiscovery, says its research institutes are brimming with innovative biotechnology...

Biotechs focusing on in-licensing, alliances for product development.(Brief Article)
July 4, 2005... Biotechnology companies large and small are increasingly focusing on acquiring the commercial rights to products, or in-licensing, says a report from Deloitte Research, entitled Critical Factors for Alliance Formation. Almost 20% of small...

Solvay makes 45M-euro bid for Girindus.(Solvay Organics GmbH)(Girindus AG)(Brief Article)
July 4, 2005... Solvay Organics GmbH, a German subsidiary of Belgium's Solvay group, has launched what it says is a friendly bid to acquire at least 51% of Girindus AG, a publicly-listed specialty chemicals company based in Bensberg, Germany. Shareholders...

UK's Xenova accepts takeover offer.(Celtic Pharmaceutical Holdings LP)(Brief Article)
July 4, 2005... UK biotechnology company Xenova says that it is recommending the acceptance of a takeover offer for all of the issued and to-be issued shares of the firm from Hamilton, Bermuda-based Celtic Pharmaceutical Holdings, a newly-formed,...

Spain's GP Pharm invests in new plant.(GP Pharm )(Brief Article)
July 4, 2005... Spanish drugs startup GP Pharm has invested 13.0 million euros ($15.8 million) to build a new drugs factory in Sant Quinti de Mediona, Spain. The company, part of the Barcelona-based drugs and cosmetics group Lipotec, will also spend 14.0...

Savient to complete sale to Ferring soon.(Brief Article)
July 4, 2005... Savient Pharmaceuticals of the USA says that it expects the closing of the sale of its global biologics manufacturing business to Ferring to occur within the next 30 days. It has received clearance on three of the five required Israeli...

PPD licenses GGTase portfolio to Duke Univ.(geranylgeranyl transferase)(Brief Article)
July 4, 2005... PPD Inc, a USA-based global provider of discovery and development services and products for pharmaceutical, biotechnology and medical device companies, has signed an agreement to exclusively license to Duke University of North Carolina, USA,...

Sanofi Rimonabant filing with US FDA.(Food and Drug Administration)(Brief Article)
July 4, 2005... French drug major Sanofi-Aventis says that the US Food and Drug Administration has acepted its New Drug Application for its anti-obesity drug Accomplia (rimonabant), a first-in-class therapy for the comprehensive management of cardiovascular...

Tentative FDA appro for Ranbaxy and Aurobindo.(Ranbaxy Laboratories Ltd.)(Aurobindo Pharma Ltd.)(Brief Article)
July 4, 2005... Indian drugmaker Ranbaxy Laboratories says that it has received tentative approval from the US Food and Drug Administration to manufacture and market a generic version of the toe and fingernail onychomycosis drug terbinafine hydrochloride,...

Generex signs R&D accord with Stallargene.(Brief Article)
July 4, 2005... Antigen Express, a subsidiary of UK biotechnology firm Generex Biotechnology, has inked a research collaboration agreement with French immunotherapy drugs producer Stallergenes. Financial details were not disclosed. The studies are to...

GeneLabs gets US OD status for Prestara.(Brief Article)
July 4, 2005... US biopharmaceutical company Genelabs Technologies says that the US Food and Drug Administration has confirmed that the indication for its experimental lupus drug Prestara (prasterone), prevention of loss of bone mineral density in systemic...

Nabi's Civacir receives orphan status from EC.(Brief Article)
July 4, 2005... The USA's Nabi Biopharmaceuticals says that, following the favorable opinion of the European Medicines Agency, the European Commission has granted Orphan Medicinal Product designation to Civacir (hepatitis c immune globulin), for the prevention...

Proteome TB test backed by Bill Gates' Foundation.(tuberculosis)(Brief Article)
July 4, 2005... The Bill Gates' Foundation for Innovative New Diagnostics has agreed to fund Australian group Proteome Sciences' research into tuberculosis. The funding will allow the group to fast-track development of its rapid antigen-based diagnostic...

Abbott and Qiagen extend distribution deal.
July 4, 2005... Dutch company Qiagen NV and US drugmaker Abbott Laboratories have extended their existing distribution agreement. Under the new terms, Abbott has gained distribution rights to a number of real-time polymerase chain reaction diagnostic tests for...

Avantogen: EU patent for immune booster.(European Union)(Brief Article)
July 4, 2005... Sydney, Australia-headquartered Avantogen, formerly known as Australian Cancer Technology, says it has been granted a European Union patent protecting the immune-enhancing adjuvant GPI-0100, a modified, semi-synthetic saponin, and its use in...

ASCC scientists closer to mass-production of blood.(Australian Stem Cell Centre)(Brief Article)
July 4, 2005... Researchers at the Melbourne-based Australian Stem Cell Centre have made a significant step towards mass-producing human blood in the laboratory, by using a more efficient process that allowing the creation of blood cells with a greatly-reduced...

Scil Tech reports positive preclinical data for ST01.(Brief Article)
July 4, 2005... Martinsreid, Germany-based Scil Technology, a biopharmaceutical company which focuses on the development of dental and orthopedic tissue regeneration products, says that its ST01 has demonstrated superior efficacy to autologous bone in an in...

Positive CHMP opinion for Schering AG's Vasovist.(Brief Article)
July 4, 2005... Schering AG of Germany says it has received a positive opinion from the Committee for Medicinal Products for Human Use for its contrast a7gent Vasovist (gadofosveset trisodium), which is indicated for contrast-enhanced magnetic resonance...

Positive EU opinion for Roche/GSK's Bonviva.(Brief Article)
July 4, 2005... Swiss drug major Roche and UK-based GlaxoSmithKline's Bonviva (ibandronic acid) has received a positive opinion from the European Committee for Medicinal Products for Human Use for the treatment of postmenopausal osteoporosis. According to...

Almirall completes Ph II of COPD drug.(Brief Article)
July 4, 2005... Barcelona, Spain-based pharmaceutical group Almirall says it has completed a large-scale, dose-ranging, Phase II clinical trial of its LAS34273 in patients with chronic obstructive pulmonary disease. Consequently, Phase III evaluation is due to...

CHMP recommends Roche's Tarceva.(Brief Article)
July 4, 2005... The European Committee for Medicinal Products for Human Use has issued a positive opinion for Swiss drugmaker Roche's Tarceva (erlotinib) for the treatment of non-small cell lung cancer which, according to William Burns, chief executive of the...

Arpida's iclaprim shows promise for pneumonia.(Brief Article)
July 4, 2005... Swiss anti-infectives group Arpida says that results from a special Phase I trial have demonstrated that its broad-spectrum antibiotic iclaprim achieves high concentrations in specific lung compartments, thereby paving the way for additional...

FDA approves Astex' IND for AT7519.(Food and Drug Administration)(Brief Article)
July 4, 2005... UK biotechnology group Astex says that the US Food and Drug Administration has accepted an Initial Drug Application for the clinical development of AT7519, its proprietary cell-cycle inhibitor, for the treatment of cancer. The agent, which...

Does Japan change? - pharma executive mobility, restructuring by P Reed Maurer.(Brief Article)
July 4, 2005... This is the season when expats move into or out of Japan, the timing largely driven by school calendars. I only have anecdotal information as to the average length of stay, but let's assume it is three to five years. I get the sense from...

Japan govt urged on cost-cutting moves.(Brief Article)
July 4, 2005... Japan's Economic and Fiscal Policy Department has compiled a recommendation, named the Basic Policies on Economic and Fiscal Management and Structural Reform, to minimize the role of government and revitalize Japan's economy. A meeting of...

IFPMA sends open letter to G-8 leaders.(International Federation of Pharmaceutical Manufacturers and Associations )
July 4, 2005... Ahead of the July 6-8 G-8 Nations meeting at Gleneagles, Scotland, the International Federation of Pharmaceutical Manufacturers and Associations has sent an open letter to the leaders of these leading countries, calling on them to secure the...

Global generics sector set for consolidation?(Brief Article)
July 4, 2005... Within the next five years, the world generics market will come under the control of a handful of major players, with fewer and fewer local or regional firms competing, Robert Weissman, chief executive of Actavis of Iceland, has told the...

Vietnam pharma "still too reliant on imports".(Brief Article)
July 4, 2005... Within five years, Vietnam's domestic pharmaceutical sector will likely increase its share of the home market from 40% to 60%, according to Cao Minh Quang, director of the Drug Administration within the Ministry of Health. However, he also...

Uganda stands firm on US-approved ARVs ban.(Brief Article)
July 4, 2005... Health officials in Uganda have confirmed that generic antiretrovirals produced by South Africa's Aspen Pharmacare and tentatively approved by the US Food and Drug Administration (Marketletter June 27) will not be allowed into the country until...

East African govts warned over Rx tax.(Brief Article)
July 4, 2005... The governments of three East African nations will lose $25.0 million worth of revenues if Uganda and Tanzania decide to waive the 10% tax on imported drugs, following the decision to do so by Kenya's government, it has been suggested. ...

Valentis completes $4.2M private placing.(valentis inc, )(Brief Article)
July 4, 2005... US firm Valentis says that it has completed a private placement of approximately 1.68 million shares of common stock and warrants to purchase up to around 840,000 additional shares at $2.50 per unit, for aggregate gross proceeds of...

Local US trial examines female sexual dysfunction.(Brief Article)
July 4, 2005... New treatment approaches for female sexual arousal disorder are being studied locally in Philadelphia, USA. FSAD is an ongoing problem of staying sexually excited. When a woman would like to have sex, but finds it is not pleasurable, this may...

GSK and Merck & Co's new drugs will drive antidepressant market in 2014.
July 4, 2005... GlaxoSmithKline's triple reuptake inhibitor NS-2359 will be the first such class of drug to market, launching in 2009 and growing steadily in the following five years, according to a new study from Decision Resources. Merck & Co's TRI,...

Jazz completes Orphan Medical buy.(Jazz Pharmaceuticals acquired of US firm Orphan Medical)(Brief Article)
July 4, 2005... Jazz Pharmaceuticals says that it has completed the previously-announced $122.6 million acquisition of fellow US firm Orphan Medical (Marketletter April 25). "The addition of Orphan Medical's products and experienced specialty salesforce...

Vectura's loss per share drops 33% to 8.6 pence.(Brief Article)
July 4, 2005... Vectura, a UK drugmaker focused on the development of inhaled drug formulations for the treatment of both lung diseases and other conditions, has posted a gross profit for the 12 months to March 31, 2005, of L3.0 million ($5.5 million), up L1.6...

EU specialty pharma: "lots to offer US biotech".(Brief Article)
July 4, 2005... In a recent meeting with industry leaders, Peter Stein, chief executive of UK drugmaker Norgine, argued that European specialty pharmaceutical firms are uniquely positioned to help US biotechnology firms break into their domestic market with...

Emergent BioSolutions acquires Microscience.(Brief Article)
July 4, 2005... US immunotherapeutics group Emergent BioSolutions has acquired UK-based Microscience, a privately-held vaccine company primarily involved in the development of innovative, proprietary vaccines and immunotherapeutics, through a share exchange...

Dutch insurers' "cheap drug" policy OKed.(Brief Article)
July 4, 2005... The Dutch competition authority, the NMA, has said it approves and supports proposals by five leading health insurers to operate preferential policies for drug suppliers, under which the companies will cover only the cheapest versions of two...

EMEA calls for suspension of Pfizer's Bextra, new warnings for other COX-2s.(European Medicines Agency)
July 4, 2005... The European Medicines Agency (EMEA) has recommended that the European Union marketing authorization for Pfizer's Bextra (valdecoxib) be suspended. Concluding its review of the COX-2 inhibitor class of non-steroidal anti-inflammatory drugs...

BioInvent initiates trial of anti-HIV drug.(Brief Article)
July 4, 2005... Lund, Sweden-headquartered drugmaker BioInvent has initiated Phase I/IIa clinical studies of its candidate anti-HIV drug, BI-201. The agent is a human antibody selected from the firm's n-CoDeR antibody library for its ability to bind to the...

New data shows CV benefits for Novartis' Diovan.(cardiovascular)(Brief Article)
July 4, 2005... Swiss drug major Novartis says that patients with moderate-to-severe hypertension treated with a combination of its Diovan (valsartan) and the diuretic hydrochlorothiazide benefited from superior blood pressure reductions over those given...

InSite prepares NDA on AzaSite.(InSite Vision Inc)(Brief Article)
July 4, 2005... The USA's InSite Vision, an ophthalmic therapeutics, diagnostics and drug-delivery specialist, has had a pre-New Drug Application meeting with the US Food and Drug Administration to discuss sections of the proposed NDA submission for AzaSite,...

Good patient reports on AstraZeneca's Atacand.(Brief Article)
July 4, 2005... A new analysis of data from a study of AstraZeneca's angiotensin receptor blocker Atacand (candesartan) found that patient perception of the treatment was better than that for placebo. Patients from the Candesartan in Heart Failure...

BI enters R&D accord with Avantium.(Boehringer Ingelheim)(Avantium International B.V.)(Brief Article)
July 4, 2005... Independent Dutch contract R&D firm Avantium has entered a research partnership with privately-held German drug major Boehringer Ingelheim to identify novel solid polymorph and salt forms utilizing the former's high-throughput screening...

Boeh Ingelheim's Aptivus for HIV gets accelerated approval by FDA.
July 4, 2005... The US Food and Drug Administration has granted German drugmaker Boehringer Ingelheim accelerated approval of its anti-HIV drug Aptivus (tipranavir) capsules for use in combination therapy, based on positive 24-week results from ongoing...

FDA OKs Keppra for children with epilepsy.(Food and Drug Administration)(Brief Article)
July 4, 2005... The US Food and Drug Administration has cleared Belgian drugmaker UCB Pharma's anti-epilepsy drug Keppra (levetiracetam) as an add-on therapy for the treatment of partial-onset seizures in children four years of age and older with epilepsy. ...

UK pharma groups struggle to keep employees, new study finds.(Brief Article)
July 4, 2005... According to the UK-based Chartered Management Institute and Remuneration Economics' National Management Salary Survey, organizations in the pharmaceutical industry are failing to keep hold of employees, despite an increased frequency of bonus...

Researchers report creation of world's smallest organic particles.(Brief Article)
July 4, 2005... Scientists at the University of North Carolina at Chapel Hill, USA, say they have developed a breakthrough method of creating the world's smallest manufactured particles for delivering drugs and other organic materials into the human body. ...

Schering AG commits to operating margin of 16% this year and 18% in 2006.
July 4, 2005... Within the framework of its FUCUS program, German drug major Schering AG says it has achieved significant milestones in streamlining its portfolio and improving its productivity. As a result, the firm told delegates at its annual analysts'...

India's Torrent buys Heumann from Pfizer.(Heumann Pharma GmbH)(Torrent Pharmaceuticals Ltd)
July 4, 2005... Indian drugmaker Torrent Pharmaceuticals has agreed to acquire Heumann Pharma GmbH & Co Generica KG of Germany through its wholly-owned German affiliate, Torrent Pharma GmbH. Heumann Pharma Generics, a subsidiary of world pharmaceutical...

Malladi of India acquires USA's Novus.(Malladi Drugs)(Novus Fine Chemicals)(Brief Article)
July 4, 2005... Chennai, India-headquartered Malladi Drugs and Pharmaceuticals has acquired Novus Fine Chemicals, a USA-based pseudoephedrine manufacturer, through a private equity raising of 10.0 billion rupees ($228.7 million), according to the Indian...

French probe of Rhodia widens.(Brief Article)
July 4, 2005... French public prosecutors have expanded their criminal investigations into alleged accounting irregularities by specialty chemicals maker Rhodia, with a raid on the country's Ministry of Finance. Current Finance Minister Therry Breton was a...

Legal group puts US FDA Rx ad reg under scrutiny.(Food and Drug Administration)
July 4, 2005... The US Food and Drug Administration, acting through its Division of Drug Marketing, Advertising and Communications, has been using letters to industry "to advance questionable legal theories and request remedial actions that the agency could...

US docs back Rx ethnic/racial group targeting.(Brief Article)
July 4, 2005... 85% of US physicians believe that drugs targeted toward specific ethnic and racial groups may have therapeutic advantages, according to a nationwide survey. The poll was conducted in response to a unanimous recommendation by a Food and...

House votes US federal funding ban on ED drugs.(erectile dysfunction )(Brief Article)
July 4, 2005... The US House of Representatives has voted 285-121 to back an amendment to a spending bill banning the new Medicare prescription drug benefit from providing enrollees with three erectile dysfunction drugs - Pfizer's Viagra (sildenafil), Lilly...

Wyeth raises FY2005 earnings guidance.(Wyeth Pharmaceuticals)(Brief Article)
July 4, 2005... US drug major Wyeth is raising its 2005 full-year guidance to $2.80-$2.90 diluted earnings per share. The company noted that high single-digit revenue increases, lower-than-expected growth in several expense items and favorable tax developments...

Private labels erode $4.5B US cough, cold, allergy and sinus market.(Brief Article)
July 4, 2005... The US market for over-the-counter cough, cold, allergy and sinus medications slid almost 4% in 2004 to just under $4.5 billion, according to a new report from Kalorama Information. The penetration of lower-priced, private-label products...

Aeolus Pharma gets capital infusion from shareholders.(Aeolus Pharmaceuticals)(Brief Article)
July 4, 2005... USA-based Aeolus Pharmaceuticals has announced that the Xmark Opportunity Funds and other investors, including the Biotechnology Value Fund, have agreed to immediately provide up to $2.5 million in funding to the firm in the form of convertible...

Fidelity takes 5.13% stake in Crucell.(Fidelity Investments)(Brief Article)
July 4, 2005... Dutch biotechnology company Crucell NV has said that Fidelity's FID Growth Company Fund has acquired a 5.13% interest in the share capital of the company. Crucell has 41.0 million shares outstanding as of May 12, 13 million of which are listed...

GeneLink expands consumer gene panel assays.(Brief Article)
July 4, 2005... US diagnostics firm GeneLink has expanded its genetic test panel to include Oxidative Stress, Basic Gene SNP panel, Comprehensive Cardio panel, Dermagenetics (skin health) panel, DNA Integrity and CoQ10 efficiency. According to the firm,...

TKT's I2S sees good Ph III results.(Transkaryotic Therapies)(Brief Article)
July 4, 2005... Transkaryotic Therapies, a US drugmaker focused on rare diseases, has reported promising top-line results from its pivotal Phase III clinical trial evaluating its investigational human enzyme replacement therapy, iduronate-2-sulfatase, for the...

Myriad's Flurizan misses Ph II endpoints.(Myriad Genetics Inc)(Brief Article)
July 4, 2005... US drugmaker Myriad Genetics says that whilst Flurizan (MPC-7869), its candidate treatment for Alzheimer's disease, missed its three Phase II primary endpoints of cognitive ability, ease of daily living and overall function, the trial was...

Strong animal data for Callisto's Atipromod.(Callisto Pharmaceuticals)(Brief Article)
July 4, 2005... The USA's Callisto Pharmaceuticals, an oncology specialist, says that encouraging results from an animal study on Atiprimod (azaspirane), its candidate treatment for multiple myeloma, have been published in the June issue of Blood the journal...